The international summit on genome editing kicked off on Tuesday at the headquarters of the National Academy of Sciences, Washington, D.C. Several scientists and researchers gathered for the three-day conference that will discuss the scientific, ethical and governance issues associated with human gene-editing technologies.
The summit particularly focuses on whether gene editing of human embryos for therapeutic reasons should be considered or ruled out altogether, The Guardian noted.
“The overriding question is when, if ever, we will want to use gene editing to change human inheritance," summit chair David Baltimore of Caltech said in his introductory remarks. “We are close to altering human heredity and we need to decide how we as a society are going to use this capability.”
According to The Australian, the process fixing defecting genes is very complicated, so much so that it has slowed down the development of genetic therapies. With gene editing technology, scientists use molecular tools to repair or replace a defective gene or delete it.
A new tool called CRISPR-Cas9 has been adopted by laboratories worldwide as it is faster, economical, and simple enough to use with minimal level of training. Scientists hope to use the tool for diseases like sickle cell, fixing the defective gene in someone's own blood-producing cells instead of implanting donated ones.
Jennifer Doudna of the University of California at Berkeley is one of the pioneers of the CRISPR technology. Doudna told reporters that it will still take several years before the tool can be used for treatment of human diseases, The Washington Post reported.
"We don't understand enough yet about the human genome, and how genes interact, and which genes give rise to certain traits to edit for human enhancement today," she said.
Marcy Darnovsky of the Center for Genetics and Society advocacy group, however, opposes heritable gene editing and calls it potentially a "society-altering technology."


Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



